Akademska digitalna zbirka SLovenije - logo
E-viri
Celotno besedilo
Recenzirano
  • Long‐term effects: Galectin...
    Yang, L.‐T.; Shu, Q.; Luo, X.‐Q.; Liu, Z.‐Q.; Qiu, S.‐Q.; Liu, J.‐Q.; Guo, H.‐J.; Li, L.‐J.; Li, M.‐G.; Liu, D.‐B.; Xia, L.‐X.; Liu, Z.‐G.; Yang, P.‐C.

    Allergy (Copenhagen), January 2018, Letnik: 73, Številka: 1
    Journal Article

    Background and Aims Mast cell activation interferes with the effects of allergen‐specific immunotherapy (SIT). Galectin‐1 (Gal‐1) is capable of regulating immune cells’ functions. This study tests the hypothesis that administration of Gal‐1 promotes and prolongs the efficacy of SIT via suppressing mast cell activation. Methods An intestinal allergy mouse model was developed. The coadministration of SIT and Gal‐1 on suppression of the allergic responses, prevention of mast cell activation, and generation of antigen‐specific regulatory T cells (Treg) in the intestine was observed in sensitized mice. Results The coadministration of Gal‐1 and SIT markedly suppressed the allergic responses in the mouse intestine vs the use of either SIT alone or Gal‐1 alone. The Gal‐1 binds to the IgE/FcɛRI complexes on the surface of mast cells to prevent mast cell activation during SIT. Gal‐1 promoted the SIT‐generated allergen‐specific Tregs in the intestine of sensitized mice. Coadministration of Gal‐1 and SIT significantly enhanced the efficacy of immunotherapy in suppressing allergic responses in the intestine, which lasted for at least for 12 months. Conclusions Long‐term effects of specific immunotherapy on intestinal allergy can be achieved with Gal‐1/SIT therapy by inhibiting mast cell activation and facilitating Treg development.